Document Detail

Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost.
MedLine Citation:
PMID:  21508068     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Hepatic arterial therapy (HAT) has been proven to be effective at palliation of hormonal symptoms of metastatic neuroendocrine tumors (NETs), as well as a means of cytoreduction. Recently, the newer modalities of yttrium-90 and drug-eluting beads with doxorubicin (DEBDOX) have been reported to be effective in the treatment of metastatic NETs. The aim of this study was to compare the safety, efficacy, and cost of selective internal radiation with DEB therapy.
METHODS: An institutional review board-approved, multicenter, multinational prospective treatment registry to investigate the safety and efficacy of yttrium-90 and doxorubicin microspheres was reviewed.
RESULTS: In all, 43 patients underwent a combined 69 HAT treatments, with 15 patients receiving 23 yttrium-90 treatments and 28 patients receiving 46 DEBDOX treatments. The extent of disease-based on the number of lesions, bilobar distribution, patient performance status, and size of largest lesion-was similar in both the yttrium-90 and DEBDOX groups. After a median follow-up of 12 months, response rates were similar with the two treatments, but then there was a significantly lower response rate in the yttrium-90 group at 12 months than in the DEBDOX group. In an evaluation of cost for the two treatments, the median cost for yttrium-90 was $25,243 and the median cost for DEBDOX was $13,400.
CONCLUSION: HAT is a safe and effective therapy in patients with unresectable NETs to the liver. The size of the lesions, total lesion volume, and expense of therapy need to be considered when choosing which HAT method is optimal.
Ryan Whitney; Vlatimil Vàlek; Joan Falco Fages; Agustin Garcia; Govindarajan Narayanan; Cliff Tatum; Mike Hahl; Robert C G Martin
Related Documents :
8607358 - Ultrasound-guided percutaneous drainage of liver abscess in children.
10869138 - Wilson's disease--early onset and lessons from a pediatric cohort in india.
19663098 - Sixty-two cases of intractable ascites due to cirrhosis treated by the modified wulings...
11778928 - Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis...
24434748 - Randomized, within-patient, clinical trial comparing fluorine-synthetic fiber socks wit...
16437598 - Relationship between body surface area and alt normalization after long-term lamivudine...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-04-20
Journal Detail:
Title:  The oncologist     Volume:  16     ISSN:  1549-490X     ISO Abbreviation:  Oncologist     Publication Date:  2011  
Date Detail:
Created Date:  2011-05-18     Completed Date:  2011-09-13     Revised Date:  2013-06-30    
Medline Journal Info:
Nlm Unique ID:  9607837     Medline TA:  Oncologist     Country:  United States    
Other Details:
Languages:  eng     Pagination:  594-601     Citation Subset:  IM    
Division of Surgical Oncology, University of Louisville School of Medicine, Louisville, Kentucky 40292, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Chemoembolization, Therapeutic*
Combined Modality Therapy
Cost-Benefit Analysis
Doxorubicin / adverse effects,  economics,  therapeutic use*
Liver Neoplasms / secondary,  therapy*
Middle Aged
Neuroendocrine Tumors / pathology*,  radiotherapy,  therapy*
Treatment Outcome
Yttrium Radioisotopes / adverse effects,  economics,  therapeutic use*
Reg. No./Substance:
0/Yttrium Radioisotopes; 23214-92-8/Doxorubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of induction dose, lactation stage and body condition on tiletamine-zolazepam anaesthesia in ...
Next Document:  Effect of sweet almond oil on survival rate and plasma cholinesterase activity of aluminum phosphide...